CareDX Shares Rise on Higher Q4 Sales Outlook

Dow Jones01-13

By Amira McKee

Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments.

The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year.

The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million.

Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million.

In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million.

"We had another quarter of strong testing services volume growth and record revenue across all segments of our business," said John W. Hanna, president and chief executive officer. "Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline."

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

January 12, 2026 11:19 ET (16:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603442015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 00:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603442015","market":"fut","top_or_hot":-1,"title":"CareDX Shares Rise on Higher Q4 Sales Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments. \n</p>\n<p>\n  The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year. \n</p>\n<p>\n  The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million. \n</p>\n<p>\n  Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million. \n</p>\n<p>\n  In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million. \n</p>\n<p>\n  \"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president and chief executive officer. \"Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CareDX Shares Rise on Higher Q4 Sales Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCareDX Shares Rise on Higher Q4 Sales Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-13 00:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments. \n</p>\n<p>\n  The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year. \n</p>\n<p>\n  The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million. \n</p>\n<p>\n  Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million. \n</p>\n<p>\n  In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million. \n</p>\n<p>\n  \"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president and chief executive officer. \"Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603442015","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603442015","pubTimestamp":1768234740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments.The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year.The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million.Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million.In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million.\"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CDNA":"CareDx"},"translate_title":"CareDX股价因第四季度销售前景上升而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":0.9},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of CareDX were higher after the medical supplies company forecast higher fourth-quarter revenue and sales gains across its business segments. \n\n\n  The stock rose 15% to $19.65 in Monday morning trading. Shares have fallen 17% in the past year. \n\n\n  The Brisbane company logged preliminary figures, predicting fourth-quarter revenue of $108 million, up 25% from the same period a year ago. Analysts polled by FactSet are expecting $102.7 million. \n\n\n  Full-year revenue is seen at $380 million, a 14% increase year-over-year. The company had previously guided for 2025 revenue of $372 million to $376 million. \n\n\n  In its 2025 fiscal year, the company said it saw gains across several sales channels, including a 10% increase in testing services revenue and 19% rise in product revenue. Patient and digital solutions revenue is seen rising 31% to about $57 million. \n\n\n  \"We had another quarter of strong testing services volume growth and record revenue across all segments of our business,\" said John W. Hanna, president and chief executive officer. \"Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.\" \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 11:19 ET (16:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603442015","isCrawlerRequest":true}